

Original Article

Prevalence of *Helicobacter pylori* and its *cagA* gene in patients with gastric cancer or peptic ulcer at an Iranian medical center

Maryam Kianmehr¹, Mohsen Zargar^{1*}, Ahmad Hormati^{2*}, Roohollah Fateh³, Razieh Nazari¹

¹Department of Microbiology, Faculty of Basic Science, Qom Branch, Islamic Azad University, Qom, Iran

²Gastroenterology and Hepatology Disease Research Center Qom University of Medical Science, Qom, Iran

³Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran

Received: 17 June, 2020; Accepted: 31 December, 2020

Abstract

Background: Iran has a high incidence rate for gastric cancer among the Middle East countries. In addition to gastric cancer, peptic ulcer is also life-threatening; thus, investigating the prevalence of *Helicobacter pylori* infection and other risk factors are essential. The present study was aimed to assess the frequency of *H. pylori* and the *cagA*-positive strains in patients with gastric cancer or peptic ulcer at a teaching hospital in Qom, one of the most populated cities of Iran.

Materials and Methods: The presence of *H. pylori* was investigated in gastric cancer and peptic ulcer biopsy specimens using the standard culture method. PCR analysis was performed to detect the presence of the *cagA* gene.

Results: The frequency of *H. pylori* isolates among 86 investigated biopsies was 20 (23.2%). Likewise, the rate of *H. pylori* was the highest when samples were examined from patients with gastric cancer (25.8%), while it was 21.8% when obtained from peptic ulcer patients. The frequency of the *cagA* gene in *H. pylori* isolates was 9 (56.2%), as confirmed by PCR.

Conclusion: Our results indicated that *H. Pylori* infection and its virulent strains are frequent and widely spread in Qom city. The *cagA* gene was present in almost half of *H. pylori* isolates from peptic ulcer or gastric cancer patients. Therefore, it is necessary to screen it in all cases with *H. pylori* infection for early detection of gastric cancer.

Keywords: *Helicobacter pylori*, *cagA*, Gastric Cancer, Peptic ulcer, Qom

***Co-corresponding Authors:** Mohsen Zargar, PhD, Department of Microbiology, Faculty of Basic Science, Qom Branch, Islamic Azad University, Qom, Iran. Email: zmohsen2002@yahoo.com. Ahmad Hormati, MD, Gastroenterology and Hepatology Disease Research Center Qom University of Medical Science, Qom, Iran. Email: hormatia@yahoo.com; <https://orcid.org/0000-0002-3108-5655>.

Please cite this article as: Kianmehr M, Zargar M, Hormati A, Fateh R, Nazari R. Prevalence of *Helicobacter pylori* and its *cagA* gene in patients with gastric cancer or peptic ulcer at an Iranian medical center. Novel Biomed. 2021;9(1):24-7.

Introduction

Helicobacter pylori is a global issue with increasing rates of infection in the world, especially in developing countries^{1,2}. Infection caused by *H. pylori* leads to various gastric diseases including chronic gastritis, peptic ulcer, and gastric cancer³⁻⁵. Recently, the World Health Organization (WHO) has classified

H. pylori as Class I carcinogen and a risk factor for gastric adenocarcinoma⁶. According to the epidemiological studies, more than 50% of the human population is infected with *H. pylori*, although there are large geographical variations⁷. Generally, the prevalence of *H. pylori* infection is higher in developing countries in comparison of developed countries^{7,8}. Although infection caused by *H. pylori* is common

among people, only a small group of the infected population develops peptic ulcer and gastric cancer⁹. Thus, factors such as host genetic, environmental, and bacterial virulence factors, such as the *cagA* gene, are considered to be responsible for neoplastic development⁹⁻¹². Poor hygiene standards and crowded households are among the important environmental factors that are associated with an increased risk of *H. pylori* infection, and these factors are usually found among those living in developing countries¹³⁻¹⁵. The cytotoxin-associated gene A (CagA) protein is the most extensively studied virulence factor of *H. pylori*. Several studies showed that CagA positive strains of *H. pylori* infection developed gastric cancer¹⁶⁻¹⁹.

In Iran, a high prevalence of *H. pylori* infections has been reported, more than 80% in the general population²⁰. To genotypes, *cagA* positive *H. pylori* strains in Iranian isolates were associated with gastric cancer²⁰⁻²². Although the prevalence of *H. pylori* and its CagA phenotype has been reported in several regions of Iran, but our knowledge is incomplete about Qom, one of the central cities of Iran. Thus, the aim of this study was to assess the frequency of *H. pylori* and *cagA*-positive strains in patients with gastric cancer or peptic ulcer at a teaching hospital in Qom, one of the most populated cities of Iran.

Methods

This study was conducted at a teaching hospital in Qom (2018-2019), Iran, from July 1 to April 20. The study protocol was approved by the internal review board of Azad University of Medical Sciences.

Study population

Patients who were diagnosed with gastric cancer or peptic ulcer, based on clinical examination, were consecutively included in the study. Experienced gastroenterologist collected three biopsy specimens during each endoscopy session: one sample from the greater curvature of the corpus and two samples from the antrum. Biopsy specimens for bacterial culture were immediately placed in transport media and brought to the laboratory on the day of endoscopy.

Isolation and identification of *H. pylori*

We followed the protocol of Dabiri and colleagues for the isolation of *H. pylori*, using Columbia blood agar supplemented with 10% horse blood, and selective supplement of *H. pylori*²¹. Then, we incubated the

inoculated plates for 4 to 7 days at 37°C under microaerophilic conditions. The *H. pylori* were identified by its biochemical profile, such as oxidase, catalase, and urease reactions²¹.

DNA extraction and PCR amplification

The extraction of DNA from *H. pylori* isolates was done from freshly harvested bacterial cells. The DNA was extracted using the DNA Mini Kit (Bio Basic, Canada) according to manufacturer specifications. For confirmation of *H. pylori* isolates, PCR for *16S rRNA* and *glmM* genes using specific primers was performed based on published papers²³.

Screening of the *cagA* gene was performed by a reaction mixture²². PCR amplification was carried out in a PCR system²¹. Sterile distilled and DNA from colonies of *H. pylori* ATCC 26695 were used as negative and positive controls, respectively. PCR product was detected by 1.5% gel electrophoresis.

Statistical analysis

Data were analyzed using statistical program for social science (SPSS) version 23.0. Qualitative data were expressed as frequency and percentage.

Results

A total of 86 biopsies were collected from patients (age range: 40 to 65 years) with either peptic ulcer (n=55) or gastric cancer (n=31). Based on the culture, the frequency of *H. pylori* among all investigated biopsies were 20 (23.2%). Likewise, the rate of *H. pylori* was the highest when samples were examined from patients with gastric cancer (25.8%), while it was 21.8% when obtained from peptic ulcer patients.

In the 16 *H. pylori* isolates which were used for molecular analysis, the frequency of the *cagA* gene in all *H. pylori* isolates was 9 (56.2%), as confirmed by PCR. Patients with gastric cancer had a greater proportion of *cagA*-positive *H. pylori* strains than those with peptic ulcers (62% vs. 50%).

Discussion

Iran is known for the high mortality rate from gastric cancer in the world and digestive tract diseases are common²⁰. *H. pylori* is one of the most important risk factors for gastric cancer. Therefore, we investigated the frequency of *H. pylori* and its *cagA* gene among patients with gastric diseases.

In the current study, the total frequency of *H. pylori* in patients with either peptic ulcer or gastric cancer was comparable with the reported prevalence in developing countries and similar to gastric cancer samples^{24,25}. In this study, we investigated the prevalence of the *cagA* gene, from *H. pylori*-positive gastric cancer and peptic ulcer samples using PCR. In Iran, the majority of *H. pylori*-infected individuals are *cagA* positive strains. The prevalence lies between 66% and 90% in different ages and geographic regions²⁰. The frequency of *cagA*-positive *H. pylori* is 90% to 95% in Asian countries, whereas it is 50% to 60% in western developed countries²⁴. In the current study, we found that 56.2% of isolates from gastric cancer or peptic ulcer patients were positive for *cagA*. This was relatively higher than the prevalence of *cagA*, as reported by other studies, such as 46% in Egyptian isolates of *H. pylori*²⁶. While in other countries in the Middle East, the *cagA* gene was even lower in *H. pylori* isolates from Jordan (26%)²⁷.

The correlation of *cagA*-positive *H. pylori* strains with gastric cancer was established in some previous studies²⁸⁻³². However, other studies reported no association between *cagA* genotype and gastric cancer patients^{33,34}. The results of different studies across several geographical regions support the unpredictability of the expression of the *cagA* gene of *H. pylori* across various populations³⁵. The variability of *cagA* gene roles in the development of gastric cancer in different ethnic groups shows the effect of host genetics or other environmental factors that moderate its expression. Thus, further studies are still needed to explore the moderating correlation of the *cagA* gene in gastric cancer patients.

This study had some limitations. First, we only obtained samples from one city in Iran. Therefore, our results might not be generalizable across the country. Second, the study population in this study came from peptic ulcer or gastric cancer patients; therefore, the specifically was not the general population. Third, an additional study using a large number of participants will be necessary to confirm our current data. Finally, further investigation is necessary to obtain samples from other regions throughout the country.

Conclusion

Our results indicated that *H. pylori* infection and its

virulent strains are frequent and widely spread in the Qom. The *cagA* gene was present in almost half of *H. pylori* isolates from peptic ulcer or gastric cancer patients. Therefore, it is necessary to screen it in all cases with *H. pylori* infection for early detection of gastric cancer.

Acknowledgment

None

References

1. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. *Helicobacter*. 2014;19 Suppl 1:1-5.
2. Leja M, Axon A, Brenner H. Epidemiology of Helicobacter pylori infection. *Helicobacter*. 2016;21:3-7.
3. Khalifa MM, Sharaf RR, Aziz RK. Helicobacter pylori: a poor man's gut pathogen? *Gut pathogens*. 2010;2(1):1-12.
4. Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: A large cohort study. *Gastroenterology*. 2020;158(3):527-536.
5. Thrift AP, El-Serag HB. Burden of gastric cancer. *Clin Gastroenterol Hepatol*. 2020;18(3):534-542.
6. World Health Organization. Biological agents. Volume 100 B. A review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization, International Agency for Research on Cancer. 2012;100(Pt B):1-441.
7. Mezmale L, Coelho LG, Bordin D, Leja M. Epidemiology of Helicobacter pylori. *Helicobacter*. 2020;25:e12734.
8. Kamogawa-Schifter Y, Yamaoka Y, Uchida T, Beer A, Tribl B, Schöniger-Hekele M, et al. Prevalence of Helicobacter pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. *PLoS One*. 2018;13(5):e0197695.
9. Chmiela M, Kupcinskas J. Pathogenesis of Helicobacter pylori infection. *Helicobacter*. 2019;24:e12638.
10. Šterbenc A, Jarc E, Poljak M, Homan M. Helicobacter pylori virulence genes. *World J Gastroenterol*. 2019;25(33):4870-84.
11. Javed S, Skoog EC, Solnick JV. Impact of Helicobacter pylori virulence factors on the host immune response and gastric pathology, in Molecular Mechanisms of Inflammation: Induction, Resolution and Escape by Helicobacter pylori. 2019, Springer. p. 21-52.
12. Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. *Toxins*. 2019;11(11):677.
13. Subsommong P, Miftahussurur M, Uchida T, Vilaichone R-k, Ratanachu-ek T, Mahachai V, et al. Prevalence, risk factors, and virulence genes of Helicobacter pylori among dyspeptic patients in two different gastric cancer risk regions of Thailand. *PLoS One*. 2017;12(10):e0187113.
14. Aminde JA, Dedino GA, Ngwasiri CA, Ombaku KS, Makon CAM, Aminde LN. Helicobacter pylori infection among patients presenting with dyspepsia at a primary care setting in Cameroon: seroprevalence, five-year trend and predictors. *BMC Infect Dis*. 2019;19(1):1-9.

15. Sarwar N, Ahmed R, Saadullah M, ullah Khan K, Kamran S, Baig FA, et al. Prevalence of *Helicobacter pylori* infection and its associated diseases in low socio-economic workers in tertiary care hospital of Lahore, Pakistan. *Biomedical Letters*. 2019;5(1):1-6.
16. Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of *Helicobacter pylori* CagA that underpin gastric carcinogenesis. *Cell Mol Immunol*. 2019; 17(1), 50-63.
17. Bakhti SZ, Latifi-Navid S, Tobnagh SG, Yazdanbod K, Yazdanbod A. Which genotype of *Helicobacter pylori*—cagA or cagE—is better associated with gastric Cancer risk? Lessons from an extremely high-risk area in Iran. *Infect Genet Evol*. 2020;85:104431.
18. Fujii Y, Murata-Kamiya N, Hatakeyama M. *Helicobacter pylori* CagA oncprotein interacts with SHIP2 to increase its delivery into gastric epithelial cells. *Cancer Science*. 2020;111(5):1596.
19. Lan K-H, Lee W-P, Wang Y-S, Liao S-X, Lan K-H. *Helicobacter pylori* CagA protein activates Akt and attenuates chemotherapeutics-induced apoptosis in gastric cancer cells. *Oncotarget*. 2017;8(69):113460.
20. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. *Arch Iran Med*. 2009;12(6):576-83.
21. Dabiri H, Jafari F, Baghaei K, Shokrzadeh L, Abdi S, Pourhoseingholi MA, et al. Prevalence of *Helicobacter pylori* vacA, cagA, cagE, oipA, iceA, babA2 and babB genotypes in Iranian dyspeptic patients. *Microb Pathog*. 2017;105:226-230.
22. Bakhti SZ, Latifi-Navid S, Zahri S. Unique constellations of five polymorphic sites of *Helicobacter pylori* vacA and cagA status associated with risk of gastric cancer. *Infect Genet Evol*. 2020;79:104167.
23. Lu J-J, Perng C-L, Shyu R-Y, Chen C-H, Lou Q, Chong SK, et al. Comparison of Five PCR Methods for Detection of *Helicobacter pylori* DNA in Gastric Tissues. *J Clin Microbiol*. 1999;37(3):772-74.
24. Castaneda CA, Castillo M, Chavez I, Barreda F, Suarez N, Nieves J, et al. Prevalence of *Helicobacter pylori* infection, its virulent genotypes, and Epstein-Barr virus in Peruvian patients with chronic gastritis and gastric cancer. *J glob oncol*. 2019;5:1-9.
25. Bibi F, Alvi SA, Sawan SA, Yasir M, Sawan A, Jiman-Fatani AA, et al. Detection and genotyping of *Helicobacter pylori* among gastric ulcer and cancer patients from Saudi Arabia. *PaK J Med Sci*. 2017;33(2):320.
26. El-Khlousy M, Rahman EA, Mostafa S, Bassam A, Elgawad HA, Elnasr MS, et al. Study of the clinical relevance of *Helicobacter pylori* virulence genes to gastric diseases among Egyptian patients. *Arab J Gastroenterol*. 2016;17(2):90-94.
27. Nimri LF, Matalka I, Bani-Hani KE, Ibrahim M. *Helicobacter pylori* genotypes identified in gastric biopsy specimens from Jordanian patients. *BMC Gastroenterol*. 2006;6(1):1-6.
28. Ekström AM, Held M, Hansson L-E, Engstrand L, Nyren O. *Helicobacter pylori* in gastric cancer established by CagA immunoblot as a marker of past infection. *Gastroenterology*. 2001;121(4):784-791.
29. Li N, Feng Y, Hu Y, He C, Xie C, Ouyang Y, et al. *Helicobacter pylori* CagA promotes epithelial mesenchymal transition in gastric carcinogenesis via triggering oncogenic YAP pathway. *J Exp Clin Cancer Res*. 2018;37(1):1-15.
30. Batista SA, Rocha GA, Rocha AM, Saraiva IE, Cabral MM, Oliveira RC, et al. Higher number of *Helicobacter pylori* CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. *BMC Microbiol*. 2011;11(1):61.
31. Meine GC, Rota C, Dietz J, Sekine S, Prolla JC. Relationship between cagA-positive *Helicobacter pylori* infection and risk of gastric cancer: a case control study in Porto Alegre, RS, Brazil. *Arg Gastroenterol*. 2011;48(1):41-45.
32. Miehlke S, Kirsch C, Agha-Amiri K, Günther T, Lehn N, Malfertheiner P, et al. The *Helicobacter pylori* vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. *Int J Cancer*. 2000;87(3):322-27.
33. Román-Román A, Martínez-Carrillo DN, Atrisco-Morales J, Azúcar-Heziquio JC, Cuevas-Caballero AS, Castañón-Sánchez CA, et al. *Helicobacter pylori* vacA s1m1 genotype but not cagA or babA2 increase the risk of ulcer and gastric cancer in patients from Southern Mexico. *Gut pathogens*. 2017;9(1):18.
34. Held M, Engstrand L, Hansson LE, Bergström R, Wadström T, Nyren O. Is the association between *Helicobacter pylori* and gastric cancer confined to CagA-positive strains? *Helicobacter*. 2004;9(3):271-77.
35. Al-Eraky DM, Helmy OM, Ragab YM, Abdul-Khalek Z, El-Seidi EA, Ramadan MA. Prevalence of CagA and antimicrobial sensitivity of *H. pylori* isolates of patients with gastric cancer in Egypt. *Infect Agents Cancer*. 2018;13(1):24.